A cost-effective approach to administering palivizumab in a centralised nurse-led community clinic.
Marshall
L
L
Kelsall
W
W
Gooding
N
N
D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics*; D003152:Community Health Nursing / Q000191:economics; D003153:Community Health Services / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D004739:England; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab